Sulphonylurea monotherapy for patients with type 2 diabetes mellitus

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Hemmingsen, Bianca ^a   Schroll, Jeppe B ^a   Lund, Søren S ^b   Wetterslev, Jørn ^a   Gluud, Christian ^a   Vaag, Allan ^c   Sonne, David Peick ^c   Lundstrøm, Lars H ^d   Almdal, Thomas P ^e  

^a Rigshospitalet   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d HILLERØD HOSPITAL   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOHEXAMIDE; CARBUTAMIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIBORNURIDE; GLICLAZIDE; INCRETIN; INSULIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS;

EID: 84880656964     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009008.pub2     Document Type: Review

References (300)

1. Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laieta MT, et al.Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006;67(2):235-40. [PUBMED: 16864814]
2. GlaxoSmithKline . Diabetes study with rosiglitazone monotherapy versus metformin or glyburide/glibenclamide. ClinicalTrials.gov 2006. [: NCT00279045]
3. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G, et al.Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010;53(9):1838-45.
4. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al.Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]. New England Journal of Medicine 2006;355(23):2427-43.
5. Krall RL. Cardiovascular safety of rosiglitazone. Lancet 2007;369(9578):1995-6. [DOI: 10.1016/S0140-6736(07)60824-1]
6. Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, et al.Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical Journal of the American Society of Nephrology 2011;6(5):1032-40.
7. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et al.A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002;25(10):1737-43.
8. Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, et al.A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabetic Medicine 2006;23(12):1289-94.
9. Center for Drug Evaluation and Research. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020741_S009_PRANDIN_TABS_AP.pdf.
10. Novo Nordisk. AGEE/DCD/046/UK. Synopsis of the trial.
11. Center for Drug Evaluation and Research. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020741_S009_PRANDIN_TABS_AP.pdf.
12. Novo Nordisk. AGEE/DCD/047/B/F/I. Synopsis of the trial.
13. Alvarsson M, Berntorp K, Fernqvist-Forbes E, Lager I, Steen L, Orn T, et al.Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study. Review of Diabetic Studies 2010;7(3):231-8.
14. Alvarsson M, Sundkvist G, Lager I, Berntorp K, Fernqvist-Forbes E, Steen L, et al.Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes, Obesity & Metabolism 2008;10(5):421-9.
15. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, et al.Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003;26(8):2231-7.
16. Rosiglitazone versus a sulfonylurea on progression of atherosclerosis in patients with heart disease and type 2 diabetes. http://clinicaltrials.gov/ct2/show/NCT00116831?term=nct00116831&rank=1 2005. [: NCT00116831]
17. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, et al.Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 2010;121(10):1176-87.
18. Ratner RE, Christopher PC, Gerstein HC, Nesto RW, Serruys PW, van Es GA, et al.Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. American Heart Journal 2008;156(6):1074-9.
19. Birkeland KI, Furuseth K, Melander A, Mowinckel P, Vaaler S. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months. Diabetes Care 1994;17(1):45-9.
20. Birkeland KI, Hanssen KF, Urdal P, Berg K, Vaaler S. A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes. Journal of Internal Medicine 1994;236(3):305-13.
21. Birkeland KI, Kilhovd B, Thorsby P, Torjesen PA, Ganss R, Vaaler S, et al.Heterogeneity of non-insulin-dependent diabetes expressed as variability in insulin sensitivity, beta-cell function and cardiovascular risk profile. Diabetic Medicine 2002;20:37-45.
22. Birkeland KI, Rishaug U, Hanssen KF, Vaaler S. NIDDM: a rapid progressive disease. Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. Diabetologia 1996;39(12):1629-33.
23. Campbell IW, Menzis DG, Chalmers J, McBain AM, Brown IRF. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabète & Métabolisme 1994;20(4):394-400.
24. Charbonnel B, Roden M, Urquhart R, Mariz S, Johns D, Mihm M, et al.Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia 2005;48(3):553-60. [PUBMED: 15739120]
25. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, QUARTET Study. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabetic Medicine 2005;22(4):399-405. [PUBMED: 15787663]
26. Collier A, Watson HH, Patrick AW, Ludlam CA, Clarke BF. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabète & Métabolisme 1989;15(6):420-5.
27. Coniff RF, Shapiro JA, Seaton TB, Bray GAB. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. American Journal of Medicine 1995;98(5):443-51. [EMBASE: 1995143472]
28. Dalzell GW, Hadden DR, Atkinson AB, Kennedy L, Weaver JA. A randomized trial of tolbutamide and metformin for persistent severe hypoglycaemia in non insulin dependent diabetes mellitus (NIDDM). Irish Endocrine Society 1986;155(9):341-42.
29. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. New England Journal of Medicine 1995; Vol. 333, issue 9:541-9.
30. Deng QW. Clinical observation on Xiayaosan modified for treatment of type 2 diabetes mellitus. Hubei Journal of Traditional Chinese Medicine 2003;25(12):31-2.
31. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factor. Clinical Therapeutics 2003;25(2):472-84.
32. Derosa G, Franzetti I, Gadaleta G, Ciccarelli L, Fogari R. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. Diabetes, Nutrition & Metabolism 2004;17(3):143-50. [PUBMED: 15334791]
33. Diehl AK, Sugarek NJ, Bauer RL. Medication compliance in non-insulin-dependent diabetes: a randomized comparison of chlorpropamide and insulin. Diabetes Care 1985;8(3):219-23. [PUBMED: 3891264]
34. Ebeling P, Teppo A, Koistinen HA, Koivisto VA. Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes. Metabolism 2001;50(3):283-7. [PUBMED: 11230779]
35. Esposito K, Giugliano D, Nappo F, Marfella R for Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110(2):214-9. [PUBMED: 15197140]
36. Feinböck C, Luger A, Klingler A, Egger T, Bielesz GK, Winkler F, et al.Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. Diabetes, Nutrition & Metabolism 2003;16(4):214-21. [PUBMED: 14768770]
37. Fineberg SE, Schneider SH. Glipizide versus tolbutamide, an open trial. Effects on insulin secretory patterns and glucose concentrations. Diabetologia 1980;18(1):49-54.
38. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes.[Erratum appears in Horm Metab Res. 2009 Dec;41(12):909]. Hormone & Metabolic Research 2009;41(12):905-9.
39. www.clinicaltrials.gov. Efficacy and safety of vildagliptin compared to gliclazide in drug naive patients with type 2 diabetes. http://clinicaltrials.gov/ct2/show/NCT00102388?term=nct00102388&rank=1. [: NCT00102388]
40. Forst T, Eriksson JW, Strotmann HJ, Bai S, Brunelle R, Gulliya KS, et al.Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes. Experimental and Clinical Endocrinology & Diabetes 2003;111(2):97-103.
41. Forst T, Hohberg C, Fuellert SD, Lübben G, Konrad T, Löbig M, et al.Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Hormone and Metabolic Research 2005;37(8):521-7.
42. Forst T, Lübben G, Hohberg C, Kann P, Sachara C, Gottschall V, et al.Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation 2005; Vol. 12, issue 7:543-50.
43. Charbonnel B, Lonnqvist F, Jones NP. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after one year of treatment in type 2 diabetic patients. Diabetes. 1999; Vol. 48 (Suppl 1).
44. GlaxoSmithKline . A multicentre, double-blind, parallel group comparative study to evaluate the efficacy, safety and tolerability of rosiglitazone vs. glibenclamide therapy, when administered to patients with type 2 diabetes mellitus. GlaxoSmithKline Clinical Study Register (http://www.gsk-clinicalstudyregister.com/) 2011. [: 49653/020]
45. Hanefeld M, Patwardhan R, Jones NP. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutrition, Metabolism, and Cardiovascular Diseases 2007;17(1):13-23. [PUBMED: 17174222]
46. Harrower AD. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas. Current Medical Research and Opinion 1985;9(10):676-80.
47. Hermann LS, Karlsson JE, Sjöstrand A. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. European Journal of Clinical Pharmacology 1991;41(3):263-5.
48. Hermann LS, Bitzén PO, Kjellström T, Lindgärde F, Scherstén B. Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus. Diabète & Métabolisme 1991;17:201-8.
49. Hermann LS, Kjellström T, Nilsson-Ehle P. Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus. Diabète & Métabolisme 1991;17:174-9.
50. Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17(10):1100-9.
51. Hermann LS, Scherstén B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabetic Medicine 1994;11(10):953-60.
52. Hoffmann J. Acarbose and glibenclamide in type-II diabetes. A comparative study on efficacy and side effects (therapeutical news) [Acarbose ung Glibenclamid bei Type-II Diabetes. Eine Vergleichsstudie zu Wirksamkeit und Nebenwirkungen]. Münchener Medizinische Wochenschrift 1990;132(31-2):487-90.
53. Hoffmann JK. Adjustment of metabolism and eating behaviour of type II diabetics. Results of a six-months treatment with glibenclamide, respectively with acarbose. Zeitschrift für Allgemeinmedizin 1992;68(29):970-7.
54. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994;17(6):561-6.
55. Hollander P, Bunkerslawson T, Bergenstal R, Mazze R. A randomized clinical trial of glyburide versus insulin using staged diabetes management to achieve euglycemia in NIDDM. Diabetologia. 1992; Vol. 35:A198.
56. Jain R, Osei K, Kupfer S, Perez AT, Zhang J. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy 2006;26(10):1388-95.
57. Jibran R, Suliman MI, Qureshi F, Ahmed M. Safety and efficacy of repaglinide compared with glibenclamide in the management of type 2 diabetic Pakistani patients. Pakistan Journal of Medical Sciences 2006;22(4):385-90. [EMBASE: 2006608997]
58. Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism 1997;83(5):1515-22.
59. Kaku K, Rasmussen MF, Nishida T, Seino Y. Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes. Journal of Diabetes Investigation 2011;2(6):441-7. [DOI: 10.1111/j.2040-1124.2011.00128.x]
60. Seino Y, Rasmussen MF, Katayama Y, Kaku K. Liraglutide is statistically superior to glibenclamide at controlling glycemia and weight, with low hypoglycemic risk, and improves beta-cell function in Japanese Subjects with T2D. Diabetes. 2009; Vol. Conference: 69th Annual Meeting of the American Diabetes Association New Orleans, LA United States. Conference Start: 20090605 Conference End: 20090609.
61. Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Current Medical Research and Opinion 2010;26(5):1013-22.
62. Zdravkovic M. Effect of liraglutide on blood glucose control in subjects with type 2 diabetes. www.clinicaltrials.gov 2006. [: NCT00393718]
63. Kamel AN, Cetinarslan B, Uysal AR, Baskal N, Corapcioglu D, Tonyukuk V. Efficacy of monotherapy with acarbose, glibenclamide, gliclazide, metformin or placebo in NIDDM patients. Diabetologia 1997;40(Suppl 1):1255.
64. Kanda T. Effects of oral antidiabetic agent on carbohydrate and lipid metabolism in mildly obese patients with diabetes mellitus: a randomized comparative study of acarbose and sulfonylurea [Keido Himan Tonyobyo Kanja no To, Shishitsu Taisha ni Oyobosu Keiko Tonyobyoyaku no Eikyo: Acarbose to SU Zai ni Yoru Randamuka Hikaku Shiken]. Rinsho to Kenkyu (The Japanese Journal of Clinical and Experimental Medicine) 1998;75(12):2757-63.
65. Kovacevic I, Profozic V, Skrabalo Z, Cabrijan T, Zjacic-Rotkvic V, Goldoni V, et al.Multicentric clinical trial to assess efficacy and tolerability of acarbose (BAY G 5421) in comparison to glibenclamide and placebo. Diabetologia Croatica 1997;26(2):83-9. [EMBASE: 1997304622]
66. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004;27(1):41-6.
67. Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, et al.Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2010; Vol. 12, issue 7:604-12.
68. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373(9662):473-81.
69. Garber A, Henry R, Ratner R, Hale P, Chang CT, Bode B. Liraglutide, a human GLP-1 analogue, offers sustained and greater reduction in HbA1c, fasting plasma glucose and weight compared with glimepiride over 2 years, with lower hypoglycaemic risk, in patients with Type 2 diabetes: LEAD-3 extension study. Diabetic Medicine. 2009; Vol. Conference: Diabetes UK Annual Professional Conference Liverpool United Kingdom, issue var.pagings.
70. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2011;13(4):348-56.
71. Garber AJ, Henry R, Ratner R, Hale P, Chang CT, Bode B. Liraglutide, a human GLP-1 analogue, maintains greater reductions in HbA1c, FPG and weight than glimepiride over 2 years in patients with type 2 diabetes: LEAD-3 extension study. Diabetologia 2009; Vol. Conference: 45th EASD Annual Meeting of the European Association for the Study of Diabetes Vienna Austria.
72. Hale P. To evaluate the effect of liraglutide versus glimepiride (Amaryl©) on haemoglobin A1c (LEAD-3). ClinicalTrials.gov 2006. [: NCT00294723]
73. Madsbad S, Kilhovd B, Lagert I, Mustajoki P, Dejgaard A. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study. Diabetic Medicine 2001;18(5):395-401.
74. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Research and Clinical Practice 1999;43(3):155-66.
75. Memisogullari R, Akcay F, Coskun A, Korkmaz U. Comparison of gliclazide treatment with diet therapy on acute phase protein levels in patients with type 2 diabetes. Turkish Journal of Medical Sciences 2009;39(1):73-6.
76. Nakamura T, Matsuda T, Kawagoe Y, Ogawa H, Takahashi Y, Sekizuka K, et al.Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism: Clinical and Experimental 2004;53(10):1382-6.
77. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Koide H. Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes/Metabolism Research and Reviews 2006;22(5):385-9.
78. Nathan DM, Roussell A, Godine JE. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study. Annals of Internal Medicine 1988;108(3):334-40.
79. Marena S, Pagani A. Miglitol vs glibenclamide in non-insulin dependent diabetes mellitus [abstract]. European Journal of Clinical Investigation 1993; Vol. 23 Suppl 1:A43.
80. Marena S, Pagani A, Montegrosso G, Boella G, Pagano A, De Michieli F, et al.Comparison of miglitol and glibenclamide in non insulin-dependent diabetic patients. Giornale Italiano di Diabetologia 1993;13(4):383-8.
81. Pagano G, Marena S, Corgiat-Mansin L, Cravero F, Giorda C, Bozza M, et al.Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Diabète & Métabolisme 1995;21(3):162-7. [PUBMED: 7556806]
82. Perriello G, Pampanelli S, Brunetti P, Di Pietro C, Mariz S, Italian Pioglitazone Study. Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes. Diabetes & Vascular Disease Research 2007;4(3):226-30.
83. Perriello G, Pampanelli S, Di Pietro C, Brunetti P, Italian Pioglitazone Study. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with type 2 diabetes. Diabetic Medicine 2006;23(3):246-52.
84. Mauersberger H, Rosenthal JH. [Wirkung von endogenem Insulin sowie Acarbose oder Glibenclamide in der Therapie der Hypertonie bei Typ-2 Diabetikern]. CF-Journal 2001;1:26-8.
85. Rosenthal J, Mauersberger H. Hypertension in type 2 diabetic patients- effects of endogenous insulin and antidiabetic therapies. American Journal of Hypertension 2000;13(4 Suppl 1):S81. [MEDLINE: 495]
86. Rosenthal JH, Mauersberger H. Effects on blood pressure of the alpha-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clinical Drug Investigation 2002;22(10):701. [MEDLINE: 492]
87. Salman S, Salman F, Satman I, Yilmaz Y, Özer E, Sengül A, et al.Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Current Medical Research and Opinion 2001; Vol. 16, issue 4:296-306.
88. Segal P, Feig PU, Schernthaner G, Ratzmann KP, Rybka J, Petzinna D, et al.The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 1997;20(5):687-91.
89. Shihara N. A comparative study of insulin secretagogue (SU agent) and insulin sensitizers (TZD). http://apps.who.int/trialsearch/trial.aspx?trialid=JPRN-UMIN000004582 2010. [: JPRN-UMIN000004582]
90. Shihara N, Kitaoka M, Inagaki N, Kadowaki T, Koumoto S, Satoh J, et al.Randomized controlled trial of single-agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes: a comparative study. Journal of Diabetes Investigation 2011;2(5):391-8. [DOI: 10.1111/j.2040-1124.2011.00115.x]
91. Fölsch UR, Spengler M, Boehme K, Sommerauer B. Efficacy of glucosidase inhibitors compared to sulphonylureas in the treatment and metabolic control of diet treated type 2 diabetic subjects: two long-term comparative studies. Diabetes, Nutrition and Metabolism 1990;3(Suppl 1):63-8.
92. Spengler M, Hänsel G, Boehme K. 6 months monotherapy of NIDDM with acarbose or glibenclamide. In: Lefébrevre PJ, Standl E editor(s). New Aspects in Diabetes. Treatment strategies with Alpha-Glucosidase Inhibitors. Third International Symposium on Acarbose:. Berlin-New York: Walter de Gryter, 1992:243-6.
93. Spengler M, Hänsel G, Boehme K. Efficacy of 6 months monotherapy with glucosidase inhibitor Acarbose versus sulphonylurea glibenclamide on metabolic control of dietary treated type II diabetics (NIDDM). Hormone and Metabolic Research.Supplement Series 1992;26(Suppl 26):50-1. [PUBMED: 1490692]
94. Spengler M, Hänsel M, Boehme K. Acarbose and glibenclamide in type II diabetes [Acarbose und Glibenclamid bei Typ-II-Diabetes]. Zeitschrift für Allgemeinmedizin 1990;65(22):606-10.
95. Spengler N, Hänsel G, Boehme K. Efficacy of 6 months monotherapy with glucosidase inhibitor acarbose versus sulphonylurea glibenclamid on metabolic control of dietary treated type II diabetics. European Journal of Clinical Investigation 1989;19 (2 Pt II):A71.
96. Sung BH, Izzo JL Jr, Dandona P, Wilson MF. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999;34(1):83-8.
97. Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, et al.Rosiglitazone reduces urinary albumin excretion. Journal of Human Hypertension 2003;17(1):7-12.
98. St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al.A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25(11):2058-64.
99. Tan M, Johns D, González Gálvez G, Antúnez O, Fabián G, Flores-Lozano F, et al.Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial. Clinical Therapeutics 2004;26(5):680-93.
100. Tan MH, Johns D, Strand J, Halse J, Madsbad S, Eriksson JW, et al.Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with type 2 diabetes. Diabetic Medicine 2004;21(8):859-66.
101. Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart R, et al.Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005;28(3):544-50. [PUBMED: 15735185]
102. Tang JZ, Mao JP, Yang ZF, Zhou ZG, Tang WL, Feng Q. Effects of glimepiride and metformin on free fatty acid in patients with Type 2 diabetes mellitus. Zhong nan da xue xue bao. Yi xue ban [Journal of Central South University. Medical Sciences] 2004;29(6):631-4.
103. Teramoto T, Yamada N, Shirai K, Saito Y. Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus. Journal of Atherosclerosis and Thrombosis 2007;14(2):86-93.
104. Tessier D, Maheux P, Khalil A, Fülöp T. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism: Clinical and Experimental 1999;48(7):897-903.
105. Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E, et al.Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism: Clinical and Experimental 2003;52(7):862-7.
106. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods and baseline results. Diabetes 1970;19(2):747-83.
107. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19:789-830. [PUBMED: 4926376]
108. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976;25:1129-53.
109. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR, et al.Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48(5):868-77.
110. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabetic Medicine 1998;15(4):297-303.
111. Mehta Z, Cull C, Stratton I, Yudkin J, Jenkinson C, Fletcher A, et al.Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999;22(7):1125-36.
112. Turner RC, Holman RR, Mathews DR, Oakes SF, Bassett PA, Stratton IM, et al.UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991;34(12):877-90.
113. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-53.
114. UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical research ed.) 1995;310(6972):83-8. [PUBMED: 7833731]
115. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR, UK Prospective Diabetes Study. Sulphonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25(2):330-6.
116. Turner RC, Holman RR, Mathews DR, Oakes SF, Bassett PA, Stratton IM, et al.UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991;34(12):877-90.
117. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854-65. [PUBMED: 9742977]
118. UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical research ed.) 1995;310(6972):83-8. [PUBMED: 7833731]
119. van de Laar FA, Lucassen PLBJ, Kemp J, Van De Lisdonk EH, Van Weel C, Rutten GEHM. Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice?: A randomised controlled trial. Diabetes Research and Clinical Practice 2004;63(1):57-65.
120. Watanabe I, Tani S, Anazawa T, Kushiro T, Kanmatsuse K. Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. Diabetes Research and Clinical Practice 2005;68(2):104-10.
121. Wolffenbuttel BH, Weber RF, van Koetsveld PM, Weeks L, Verschoor L. A randomized crossover study of sulphonylurea and insulin treatment in patients with type 2 diabetes poorly controlled on dietary therapy. Diabetic Medicine 1989;6(6):520-5.
122. Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999;22(3):463-7.
123. Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabetic Medicine 2005;22(8):980-5.
124. Zhang YN, Cui C, Chang ML, Wu W, Yu WG, Liu FC, Tan N, Zhang JC. Interventional effects of rosiglitazone in type 2 diabetes elderly male patients combined with atherosclerosis. Chinese Journal of Clinical Rehabilitation 2005;9(39):58-61.
125. Adetuyibi A, Ogundipe O. A comparative trial of glipizide, glibenclamide and chlorpropamide in the management of maturity-onset diabetes mellitus in Nigerians. Current Therapeutic Research Clinical and Experimental 1977;21(4):485.
126. Adlung J, Koch CD. Influence of tolbutamide on serum glucose level, specific activity of glucose and glucose oxidation in severe diabetes. International Journal of Clinical Pharmacology, Therapy and Toxicology 1974;10(2):128-35. [PUBMED: 4448554]
127. Ahuja MM, Gupta SP, Sehgel VK. Efficacy of glibenclamide in maturity-onset diabetics as maintenance therapy. Hormone and Metabolic Research 1973;5(3):160-3. [PUBMED: 4197503]
128. Akanuma Y, Kosaka K, Kanazawa Y, Kasuga M, Fukuda M, Aoki S. Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. Diabetes Research and Clinical Practice 1988;5(2):81-90. [PUBMED: 3416710]
129. Almer LO. Effect of chloropropamide and gliclazide on plasminogen activator activity in vascular walls in patients with maturity onset diabetes. Thrombosis Research 1984;35(1):19-25.
130. Aman M, Jawad F, Sultana S, Waiz-ul-Haq, Nanji R. Clinical trial with glipizide in uncomplicated maturity onset diabetes mellitus. JPMA - Journal of the Pakistan Medical Association 1977;27(3):293-5.
131. Baba S, Nakagawa S, Takebe K, Goto Y, Maezawa H, Takeda R, et al.Double-blind randomized control study with gliclazide. Rinsho Hyoka (Clinical Evaluation) 1983;11(1):51-94.
132. Balabolkin MI, Morozova TP, Zhizhina SA, Novikova NV, Nepsha VD. The effect of diamicron on various blood coagulation indices in patients with type II diabetes mellitus [Vliianie diamikrona na nekotorye pokazateli svertyvaiushchei sistemy krovi u bol'nykh sakharnym diabetom II tipa.]. Klinicheskaia Meditsina 1983;61(4):66-8. [PUBMED: 6865293]
133. Balabolkin MI, Nedosugova LV. Effect of long-term therapy with sulfanylurea preparations on the relation of insulin secretion and the insulin-binding capacity of its receptors. Terapevticheskii Arkhiv 1988;60(12):91-6.
134. Banerji MA, Chaiken RL, Lebovitz HE. Prolongation of near-normoglycemic remission in black NIDDM subjects with chronic low-dose sulfonylurea treatment. Diabetes 1995;44(4):466-70.
135. BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. New England Journal of Medicine 2009;360(24):2503-15.
136. Bellomo DA, Stefanelli G, Laviola L, Giorgino R, Giorgino F. Nateglinide provides tighter glycaemic control than glyburide in patients with type 2 diabetes with prevalent postprandial hyperglycaemia. Diabetic Medicine 2011; Vol. 28, issue 5:560-6.
137. Belovalova IM, Gamburtseva TD, Kniazeva AP, Matveeva LS, Starosel'tseva LK. The nature of the pancreatic hormone secretion and of the metabolic indices during the acute and chronic administration of peroral hypoglycemic preparations. Problemy Endokrinologii 1990; Vol. 36, issue 1:14-20.
138. Ben Khelifa F, Sellami S, Abid M, Fitouhi B, Jerbi A, Jedidi S, et al.Comparison of the hypoglycemic effect of 2 presentations--of glibenclamide. La Tunisie Medicale 1988;66(12):887-93.
139. Berber MJ, Tomkin GH. The effects of gliclazide in diabetes: a comparison with tolbutamide. Irish Journal of Medical Science 1982;151(2):46-9.
140. Bernas M, Czech A, Taton J. Relative effectiveness of tolbutamide, chlorpropamide and gliclazide. Polski Tygodnik Lekarski 1992; Vol. 47, issue 1-2:35-9.
141. Berry EM, Bar-On H. Comparison of sulphonylurea and insulin treatment on lipid levels in maturity-onset diabetic men and women. Israel Journal of Medical Sciences 1981; Vol. 17, issue 5:384-7.
142. Blumenbach L, Kiesselbach N, Lehnert J. Further results of a multi-centre clinical trial with the oral antidiabetic drug glisoxepide [Neue Ergebnisse einer multizentrischen klinischen Studie mit dem oralen Antidiabetikum Glisoxepid]. Arzneimittel-Forschung 1976;26(5):931-43.
143. Bruns W, Jutzi E, Staritz B, Willkommen G, Willkommen G. Treatment of type II diabetics (non-insulin-dependent) for sulphonylurea secondary failure - combined therapy, using glibenclamid and insulin. Zeitschrift fur Klinische Medizin 1990;45(11):983-6.
144. Calvagno M, Acacia E, Kremer P, Marowsky C, Maccione E, Taddey N, et al.Clinical and biomedical study of a sulphonylurea hypoglycemic agent with action at vascular level [Estudio clinico y biomedico de un hipoglucemiante sulfonilureico con accion a nivel vascular]. Semana Médica 1983;162(20):799-808.
145. Cefalu WT, Bell-Farrow A, Wang ZQ, McBride D, Dalgleish D, Terry JG. Effect of glipizide GITS on insulin sensitivity, glycemic indices, and abdominal fat composition in NIDDM. Drug Development Research 1998;44(1):1-7.
146. Ceriello A, Johns D, Widel M, Eckland DJ, Gilmore KJ, Tan MH. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005;28(2):266-72.
147. Chan TK, Chan V, Teng CS, Yeung RTT. Effects of gliclazide and glibenclamide on platelet function, fibrinolysis and metabolic control in diabetic patients with retinopathy. Semaine des Hopitaux 1982;58(19):1197-200.
148. Chandra ST, Priya G, Khurana ML, Jyotsna VP, Sreenivas V, Dwivedi S, et al.Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes. Diabetes Technology & Therapeutics 2008;10(5):363-8. [PUBMED: 18715212]
149. Chen H. Pharmacokinetic and clinical study on glibenclamide. Zhonghua Yi Xue Za Zhi 1987;67(10):533-5.
150. Cortinovis A, Crippa A, Sciacca V, Caravaggio V, Crippa M. [Modificazioni emoreologiche, metaboliche ed emocogulative in diabetici in trattamento con sulfaniluree]. Minerva Medica 1998;79(5):391-8.
151. Derosa G, Maffioli P, Salvadeo SAT, Ferrari I, Ragonesi PD, Querci F, et al.Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology and Therapeutics 2010;12(3):233-40.
152. Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Hormone and Metabolic Research 1996; Vol. 28, issue 9:426-9. [PUBMED: 8911977]
153. Dowey KE, Grant AP, Hayes JR. Glipizide evaluation after a one year trial in maturity onset diabetics. Ulster Medical Journal 1979;48(1):65-8.
154. Drouin P. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study. Journal of Diabetes & its Complications 2000;14(4):185-91.
155. Drouin P, Standl E, Diamicron MR. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2004;6(6):414-21.
156. Duprey J, Lubetzki J. Insulin secretion in maturity-onset diabetes mellitus. Effects of the prolonged administration of glybutamide [L'insulino-secretion dans le diabete de la maturite. Effets de l'administration prolongee de glybutamide.]. La Presse Medicale 1971;79(54):2469-71. [PUBMED: 5157896]
157. Engelhardt HT, Vecchio TJ. The long-term effect of tolbutamide on glucose tolerance in adult, asymptomatic, latent diabetics. Metabolism 1965; Vol. 14:885-90.
158. Ferner RE, Antsiferov ML, Kelman AW, Alberti KGMM, Rawlins MD. The relationships between dose and concentration of tolbutamide and insulin and glucose responses in patients with non-insulin-dependent diabetes. European Journal of Clinical Pharmacology 1991; Vol. 40, issue 2:163-8.
159. Forst T, Weber M, Pfützner A, Löbig M, Hohberg C, Fuchs W. C-peptide and intima media thickness in type 2 diabetes mellitus treated with pioglitazone. Diabetes Stoffwechsel Und Herz 2011; Vol. 20, issue 2.
160. Fuchs K. Glipizide versus tolbutamide in maturity-onset diabetes, an open comparative study. Diabetologia 1973;9(Suppl):351-5.
161. Garber AJ, Bruce S, Fiedorek FT. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study. Clinical Therapeutics 2002;24(9):1401-13.
162. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D, Glyburide/Metformin Initial Therapy Study. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes, Obesity & Metabolism 2002;4(3):201-8.
163. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. Journal of Clinical Endocrinology & Metabolism 2003;88(8):3598-604.
164. Gargiulo P, Caccese D, Pignatelli P, Brufani C, De Vito F, Marino R, et al.Metformin decreases platelet superoxide anion production in diabetic patients. Diabetes/Metabolism Research and Reviews 2001; Vol. 18, issue 2:156-9.
165. Giles TD, Miller AB, Elkayam U, Bhattacharya M, Perez A. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. Journal of Cardiac Failure 2008;14(6):445-52.
166. Giles TD, Elkayam U, Bhattacharya M, Perez A, Miller AB. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congestive Heart Failure 2010;16(3):111-7.
167. Goldberg RB, Holvey SM, Schneider J, Bansal S, Blonde L, Boden G, et al.A dose-response study of glimepiride in patients with niddm who have previously received sulfonylurea agents. Diabetes Care 1996;19(8):849-56.
168. Groop L, Widén E, Franssila-Kallunki A, Ekstrand A, Saloranta C, Schalin C, et al.Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989;32(8):599-605.
169. Gudat U, Bungert S, Kemmer F, Heinemann L. The blood glucose lowering effects of exercise and glibenclamide in patients with type 2 diabetes mellitus. Diabetic Medicine 1998;15(3):194-8.
170. Gurling KJ. A comparison of glibenclamide with chlorpropamide in newly diagnosed maturity-onset diabetes. Postgraduate Medical Journal 1970;Suppl:66-9.
171. Happ J, Beyer J, Nest E, Fröhlich A, Althoff PH, Schöffling K. Blood sugar, serum insulin, nonesterified fatty acids and somatotropin in daily profile in adult diabetics under monotherapy with various sulfonylureas [Blutzucker, Seruminsulin, unveresterte Fettsäuren und Wachstumshormon im Tagesprofil bei Erwachsenen-Diabetikern unter Monotherapie mit verchiedenen Sulfonylharnstoffen]. Arzneimittel-Forschung 1974;24(8):1228-34.
172. Haupt E, Beyer J, Schoffling K. The influence of various sulphonylurea derivatives on the oral glucose-tolerance tests in healthy subjects and obese and maturity-onset diabetics (author's transl) [German]. Deutsche Medizinische Wochenschrift 1974;99(9):385-8.
173. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, et al.Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001;24(6):983-8.
174. Howes LG. Cardiovascular effects of sulphonylureas: role of K(ATP) channels. Diabetes, Obesity and Metabolism 2000; Vol. 2, issue 2:67-73.
175. Hristov V, Sheinkova G, Simeonov S, Botushanov N, Valkov Y, Tzinlikov I. Clinical assessment of glimepiride (Amaril) in the treatment of type 2 diabetes mellitus patients (results of a multicenter study). Endocrinologia 2002;7(1):30-5.
176. Hussain SA. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. Journal of Medicinal Food 2007;10(3):543-7. [PUBMED: 17887949]
177. Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M, et al.Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diabetes Research and Clinical Practice 2005;68(3):250-7. [PUBMED: 15936468]
178. Irsigler K, Ogris E, Steinhardt T, Brandle J, Regal H, Zdolsek I. Comparison of glibenclamide, gliquidone, glisoxepide and placebo in maturity onset diabetics of differing degrees of severity (author's transl) [German]. Wiener Klinische Wochenschrift 1979;91(16):541-50.
179. Ishizuka T, Taniguchi O, Yamamoto M, Kajita K, Nagashima T, Takeda N, et al.Thrombin-induced platelet aggregation, phosphoinositide metabolism and protein phosphorylation in NIDDM patients treated by diet, sulphonylurea or insulin. Diabetologia 1994;37(6):632-8.
180. Jackson WP, Vinik AI. Preliminary trial of a powerful new sulphonylurea in maturity-onset diabetes-HB419 (glibenclamide). South African Medical Journal 1969;43(32):1002-4.
181. Jerums G, Murray RML, Seeman E. Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study. Diabetes Research and Clinical Practice 1987;3(2):71-80.
182. Johnston AT, Ireland JT. A comparison of glibenclamide and chlorpropamide in the treatment of non-obese maturity onset diabetics. Postgraduate Medical Journal 1970;December(Suppl):98-100. [PUBMED: 5500517]
183. Josephkutty S, Potter JM. Comparison of tolbutamide and metformin in elderly diabetic patients. Diabetic Medicine 1990;7(6):510-4.
184. Joshi A, Gupta BS, Sharma SK, Singh V, Chaturvedi MK, Singhal A, et al.Comparative study of repaglinide with glibenclamide in the management of type 2 diabetes mellitus [abstract no: 12]. Journal of the Association of Physicians of India 2002; Vol. 50.
185. Kakhnovskii IM, Koroleva TV, Zakharchenko VN, Larionov SN. A comparative evaluation of the effect of glurenorm and sulfonylurea preparations on the intravascular microcirculatory indices in type-II diabetes mellitus. Problemy Endokrinologii 1993;39(2):7-9.
186. Kanoun F, Ben Rehaiem B, Mekaouar A, Abdennebi E, Ftouhi B, Idriss S, et al.Secondary failure of oral hypoglycaemic agents (OHA) in the treatment of non insulin-dependent diabetic (NIDDM) patients: effects of carbohydrate and caloric restrictive diet. Revue Francaise d'Endocrinologie Clinique - Nutrition et Metabolisme 1996;37(6):529-36.
187. Langenfeld MR, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, et al.Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005;111(19):2525-31.
188. Lecomte MJ, Luyckx AS, Lefebvre PJ. Plasma glucagon and clinical control of maturity-onset type diabetes. Effects of diet, placebo and glipizide. Diabete et Metabolisme 1977;3(4):239-43. [: 340296]
189. Levy J, Vandenberg M, Grunberger G. Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus. Effects on blood pressure and glucose tolerance. American Journal of Hypertension 1995;8(5 Pt 1):445-53.
190. Li H, Li W, Gu Y, Han Y, Wang J, Xu B, et al.Comparison of continual insulin or secretagogue treatment in type 2 diabetic patients with alternate insulin-secretagogue administration. [Erratum appears in Diabetes Res Clin Pract. 2009 Sep;85(3):342]. Diabetes Research & Clinical Practice 2009;84(2):158-62.
191. Lim P, Khoo OT. Metformin compared with tolbutamide in the treatment of maturity-onset diabetes mellitus. Medical Journal of Australia 1970;1(6):271-3.
192. Lindbjerg IF, Christoffersen EM, Kuusisto A, Lodahl K, Sagild U, Sterling N, et al.Clinical comparison between glibornuride (Glutril) and tolbutamide in maturity-onset diabetes: a controlled double-blind trial. Current Therapeutic Research, Clinical and Experimental 1976;20(3):277-82.
193. Liu GC, Coulston AM, Lardinois CK, Hollenbeck CB, Moore JG, Reaven GM. Moderate weight loss and sulfonylurea treatment of non-insulin-dependent diabetes mellitus. Combined effects. Archives of Internal Medicine 1985;145(4):665-9.
194. Lomuscio A, Vergani D, Marano L, Castagnone M, Fiorentini C. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction. Coronary Artery Disease 1994;5(9):767-71.
195. Mafauzy M. Repaglinide versus glibenclamide treatment of type 2 diabetes during Ramadan fasting. Diabetes Research & Clinical Practice 2002;58(1):45-53.
196. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D Ágostino RB, et al.Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296(21):2572.
197. Meneilly GS. Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes. Diabetes Technology and Therapeutics 2011;13(1):63-5.
198. Mogensen EF, Worm J, Mikkelsen BO. Clinical comparison between glibornuride (Glutril) and glibenclamide in maturity-onset diabetes: a controlled double-blind trial. Current Therapeutic Research, Clinical and Experimental 1976;19(6):559-64.
199. Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. Journal of Diabetes and Its Complications 2000;14(5):250-4.
200. Nikkilä K, Groop L. Glibenclamide and gliquidone in the treatment of non-insulin-dependent diabetes mellitus. Acta Medica Scandinavica 1982;211(1-2):13-7.
201. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al.Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; Vol. 299, issue 13:1561-73. [PUBMED: 18378631]
202. Noury J, Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabète & Métabolisme 1991;17(1 Pt 2):209-12.
203. Omrani GHR, Lari OB, Mehdizadeh AR, Zare N, Saadat N. Comparison of serum homocysteine level in metformin versus glibenclamide treated type 2 DM patients. Iranian Journal of Diabetes and Lipid Disorders 2005; Vol. 4, issue 2:E4+E4i-viii.
204. Osei K, Rhinesmith S, Gaillard T, Schuster D. Metabolic effects of chronic glipizide gastrointestinal therapeutic system on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant, first-degree relatives of African American patients with type 2 diabetes: new insights on mechanisms of action. Metabolism: Clinical and Experimental 2003;52(5):565-72.
205. Papa G, Fedele V, Rizzo MR, Fioravanti M, Leotta C, Solerte SB, et al.Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: a randomized, open-label, two-period, cross-over trial. Diabetes Care 2006;29(8):1918-20.
206. Perez A, Spanheimer R, Khan M. Glycaemic control in patients with type 2 diabetes: the effects of pioglitazone vs glyburide in a 3-year randomized double-blind trial. Diabetologia 2006;49:0807.
207. Quatraro A, Consoli G, Magno M, Caretta F, Nardozza A, Ceriello A, et al.Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug?. Annals of Internal Medicine 1990;112(9):678-81.
208. Rao VU, Alokozai D, Voloshko P, Schiller NB. Effect of the dual peroxisome proliferator-activated receptor alpha/gamma agonist, muraglitazar, on cardiac structure and function in type 2 diabetic patients. Journal of the American College of Cardiology. 2010; Vol. Conference: American College of Cardiology's 59th Annual Scientific Session and i2 Summit: Innovation in Intervention Atlanta, GA United States.
209. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanfeld M, et al for the RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373(9681):2125-35.
210. Rosenstock J, Corrao PJ, Goldberg RB, Kilo C. Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus. Clinical Therapeutics 1993;15(6):1031-40.
211. Rupprecht E, Konig E, Limmer J. Clinical evaluation of gliquidone-short acting sulfonylurea derivative-comparison with glibenclamide and gliclazide. Polski Tygodnik Lekarski 1993;48(Suppl 1):31-2.
212. Saadatnia M, Siavash M, Amini A, Hamid A. Cognitive impairment in type 2 diabetic patients using metformin or sulfonylurea: a comparative study. Alzheimer's and Dementia 2009; Vol. Conference: Alzheimer's Association International Conference on Alzheimer's Disease Vienna Austria.
213. Sami T, Kabadi UM, Moshiri S. The effect on metabolic control of second-generation sulfonylurea drugs in patients with NIDDM after secondary failure to first-generation agents. Journal of Family Practice 1996;43(4):370-4.
214. Sasahara T, Jerums G, Nestel P. Effects of insulin therapy and glycemic control on distribution of HDL alpha and pre-beta subfractions in non insulin-dependent diabetic subjects. Nutrition, Metabolism, and Cardiovascular Diseases 1999;9(1):19-24.
215. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al.GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. European Journal of Clinical Investigation 2004; Vol. 34, issue 8:535-42.
216. Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, et al.Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. International Journal of Clinical Practice 2010;64(5):562-76.
217. Shinoda Y, Inoue I, Nakano T, Goto S, Katayama S. Treatment with glimepiride, but not mitiglinide and short-acting insulin, resists body weight and abdominal fat reduction under dietary energy-restriction. Journal of Diabetes. 2009; Vol. Conference: 3rd International Congress on Prediabetes and the Metabolic Syndrome Nice France. Conference Start: 20090401 Conference End: 20090404. Conference Publication.
218. Speiser P, Schernthaner G. Sulfonylurea omission leads to a significant deterioration of metabolic state in diabetes mellitus type II: a placebo-controlled double-blind study. Klinische Wochenschrift 1989;67(Suppl 16):204.
219. Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Safety 2009;32(9):787-800.
220. Tovi J, Svanborg E, Nilsson BY, Engfeldt P. Diabetic neuropathy in elderly type 2 diabetic patients: effects of insulin treatment. Acta Neurologica Scandinavica 1998;98(5):346-53.
221. Toyota T, Fukao A, Kaneko T, Suda T, Maruhama Y, Sato J. Clinical Evaluation of glimepiride (HOE490) in non-insulin-dependent diabetes mellitus: a double-blind placebo-controlled study/phase III additional study. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines) 1997;13(17):4457-78.
222. Tsumura K. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide. Diabetes Research and Clinical Practice 1995;28 Suppl:147-9.
223. Umpierrez GE, Clark WS, Steen MT. Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises. Diabetes Care 1997;20(4):479-83.
224. Vray M, Attali JR. Randomized study of glibenclamide versus traditional Chinese treatment in type 2 diabetic patients. Diabète & Métabolisme 1995;21(6):433-9.
225. Wang WL, Zhang BZ, Zhang SL, Xu DF, Wei XH. Multicenter randomized controlled trial of domestic gliclazide and tolbutamide in the treatment of non-insulin-dependent diabetes mellitus. Chinese Journal of Pharmacoepidemiology 1994;3(3):119-21.
226. Wu CZ, Pei D, Hsieh AT, Wang K, Lin JD, Lee LH, et al.Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. Archives of Pharmacal Research 2010; Vol. 33, issue 3:411-6.
227. Yang Z, Zhou Z, Li X, Huang G, Lin J. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Research and Clinical Practice 2009; Vol. 83, issue 1:54-60.
228. Zhou, W . 60 cases of type II diabetes mellitus treated by Zishen Jiangtang decoction compared with 25 cases treated by glibenclamide in the control group. Zhejiang Journal of Traditional Chinese Medicine [Zhe Jiang Zhong Yi Za Zhi] 1999, issue 8:328.
229. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20(7):1183-97. [PUBMED: 9203460]
230. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999;22 Suppl 1:S5-19.
231. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26 Suppl 1:S5-20. [PUBMED: 12502614]
232. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008;31 Suppl 1:S12-54. [PUBMED: 18165335]
233. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219. [PUBMED: 12543843]
234. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al.Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Annals of Internal Medicine 2011;154(9):602-13. [PUBMED: 21403054]
235. Black C, Donnelly P, McIntyre L, Royle P, Shepherd JJ, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD004654.pub2]
236. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al.Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Annals of Internal Medicine 2007;147(6):386-99. [PUBMED: 17638715]
237. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive--trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98. [PUBMED: 18824466]
238. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
239. Damsbo P, Clauson P, Marbury TC, Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 1999;22(5):789-94. [PUBMED: 10332683]
240. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al.Evaluating non-randomised intervention studies. Health Technology Assessment (Winchester, England) 2003;7(27):iii-x, 1-173. [PUBMED: 14499048]
241. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
242. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
243. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;358(9294):1709-16. [PUBMED: 11728565]
244. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nature Clinical Practice. Endocrinology & Metabolism 2005;1(1):22-31. [PUBMED: 16929363]
245. Center for Drug Evaluation and Research. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020741_S009_PRANDIN_TABS_AP.pdf.
246. Fine D, Shedrovilzky H. Hyponatremia due to chlorpropamide. A syndrome resembling inappropriate secretion of antidiuretic hormone. Annals of Internal Medicine 1970;72(1):83-7. [PUBMED: 5410399]
247. Fleming TR. Addressing missing data in clinical trials. Annals of Internal Medicine 2011;154:113-7.
248. Gamble C, Hollis S. Uncertainty method improved on best-worst case analysis in a binary meta-analysis. Journal of Clinical Epidemiology 2005;58(6):579-88. [PUBMED: 15878471]
249. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007;30(2):389-94. [PUBMED: 17259518]
250. Gerich JE. Oral hypoglycemic agents. New England Journal of Medicine 1989;321(18):1231-45. [PUBMED: 2677730]
251. Gluud LL. Bias in clinical intervention research. American Journal of Epidemiology 2006;163(6):493-501. [PUBMED: 16443796]
252. Harrower AD. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Safety 2000;22(4):313-20. [PUBMED: 10789825]
253. Henquin JC. The fiftieth anniversary of hypoglycaemic sulphonamides. How did the mother compound work?. Diabetologia 1992;35(10):907-12. [PUBMED: 1451945]
254. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
255. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670-4. [PUBMED: 10480822]
256. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine 2008;359(15):1577-89. [PUBMED: 18784090]
257. International Conference on Harmonisation Expert Working Group. ICH harmonised tripartite guideline. Guideline for good clinical practice //1997 CFR & ICH Guidelines. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. USA: Barnett International/PAREXEL 1997.
258. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al.Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55(6):1577-96. [PUBMED: 22526604]
259. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21(9):1414-31. [PUBMED: 9727886]
260. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
261. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
262. Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs & Aging 2000;17(5):411-25. [PUBMED: 11190420]
263. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597-600.
264. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. American Journal of Medicine 2002;113 Suppl 6A:3S-11S. [PUBMED: 12431757]
265. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al.The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine 1999;6(7):1-28. [DOI: 10.1371/journal.pmed.1000100]
266. Liu JP, Zhang M, Wang W, Grimsgaard S. Chinese herbal medicines for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003642.pub2]
267. Liu RM, Jia P, Tang Y. Glimepiride therapy for type 2 diabetes mellitus: a systematic review. Chinese Journal of Evidence-Based Medicine 2009;9(10):1094-8.
268. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane database of systematic reviews 2012;Issue 12. Art. No.: MR000033. DOI: 10.1002/14651858.MR000033.pub2.. [PUBMED: 23235689]
269. Markkanen A, Oka M, Petola P. Carbutamide in diabetes: report of a long-term trial, with special reference to late failures. BMJ 1960;1(5179):1089-91. [PUBMED: 14421259]
270. Richter B, Bergerhoff K, Paletta G, Bandeira-Echtler E, Lerch C. Cochrane Metabolic and Endocrine Disorders Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2007, Issue 4. Art. No.: ENDOC.
271. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
272. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al.Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52(1):17-30. [PUBMED: 18941734]
273. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
274. Ooi CP, Yassin Z, Hamid T-A. Momordica charantia for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD007845.pub2]
275. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clinical Trials 1997;18(6):580-93; discussion 661-6. [PUBMED: 9408720]
276. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 1998;351(9095):47-52. [PUBMED: 9433436]
277. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim S. Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD006060.pub2]
278. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim S. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006063.pub2]
279. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD006739.pub2]
280. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD002966.pub3]
281. Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38. [PUBMED: 22945832]
282. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al.Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. European Heart Journal 2011;32(15):1900-8. [PUBMED: 21471135]
283. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
284. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, et al.Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Archives of Internal Medicine 2008;168(19):2070-80. [PUBMED: 18955635]
285. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care; Meta-analysis in Context. London: BMJ Publishing Group, 2001:189-208.
286. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al.Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. International Journal of Epidemiology 2009;38(1):276-86. [PUBMED: 18824467]
287. Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al.The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study. PLoS ONE 2011;6(10):e25491.
288. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). http://www.ctu.dk/tsa/downloads.aspx 2011.
289. Copenhagen Trial Unit. Trial sequential analysis. 9.0 beta. Copenhagen: Copenhagen Trial Unit, 2011. [: http://www.ctu.dk/tsa/]
290. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53. [PUBMED: 9742976]
291. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854-65. [PUBMED: 9742977]
292. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD003639.pub2]
293. Vist GE, Bryant D, Somerville L, Birminghem T, Oxman AD. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.MR000009.pub4]
294. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75. [PUBMED: 18083463]
295. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects meta-analyses. BMC Medical Research Methodology 2009;9(86):1-12. [PUBMED: 20042080]
296. WHO Expert Committee on Diabetes Mellitus. Second report. Technical Report Series 646. World Health Organization 1980.
297. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. Technical Report Series 727. World Health Organization 1985.
298. Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15:539-53.
299. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
300. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. New England Journal of Medicine 2007;357(11):1121-35. [PUBMED: 17855673]